Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Friday 08 January 2021 12:14 pm  |  Updated:  Friday 08 January 2021 1:45 pm

Moderna’s Covid vaccine gets green light from UK

By: Poppy Wood

Add as a preferred source on Google

The UK’s medicines regulatory body has authorised the Moderna vaccine for emergency use, the company has announced, in a major boost to the nation’s vaccination efforts.

The US-made drug becomes the third coronavirus vaccine granted approval for use by the Medicines & Healthcare products Regulatory Agency (MHRA) in Britain, as ministers ramp up plans to vaccinate more than 13m people by mid-February.

The government has ordered an additional 10m doses of the jab, taking the UK’s total order to 17m.

The drug proved 94 per cent effective in protecting against coronavirus in clinical trials.

The vaccine’s approval comes as an unexpected boost for the country’s ambitious vaccination programme, with the jab previously anticipated to be delivered much later this year. 

MHRA chief executive Dr June Raine said: “Today’s approval brings more encouraging news to the public and the healthcare sector. Having a third Covid-19 vaccine approved for supply following a robust and thorough assessment of all the available data is an important goal to have achieved and I am proud that the agency has helped to make this a reality.”

The US granted emergency authorisation for the Moderna vaccine in mid-December, with the EU following suit yesterday.

The government has spread orders across seven potential vaccines that use a variety of methods, stressing that vaccination across the population will not be achieved by a “one size fits all method”.

Read more

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Around 1.5m people have already received at least one dose of either the Astrazeneca or Pfizer vaccine, including almost a quarter of all over-80s in England.

However, the Moderna vaccine will not be available for use straight away, with the first doses not expected to arrive until the spring.

The Prime Minister earlier this week said wide scale vaccine roll-out would require the combined efforts of the NHS and the Armed Forces as the government works “absolutely flat out” to vaccinate the nation before lockdown restrictions are lifted.

Professor Chris Whitty, England’s chief medical officer, said that the vaccine timetable was “realistic but not easy”.

“The NHS is going to have to use multiple channels to get this out, but they are very determined to do this. But that does not make it easy,” he said.

Nadhim Zahawi, the UK’s vaccine tsar yesterday announced that community pharmacy networks will be “very much involved” in plans to vaccinate the most vulnerable members of the population over the next seven weeks.

Current government plans will see vaccines given to GPs to be rolled out to the public, then national vaccination centres, and then distributed across local pharmacies, Zahawi announced.

“The NHS has a very clear plan and I’m confident that we can meet it,” he said, adding that it would require a “Herculean effort” to roll out the jab by mid-February.

Read more

GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • Clarkson’s Farm and why businesses must stop blaming the weather

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Lloyd’s deputy chair: The City is a club in the best sense

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

More from City PM

  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

    Tech
    GSK said total sales fell by two per cent in the third quarter
  • Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Business Wire
  • AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas

    Business Wire
  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Banks call for ‘political mandate’ to bolster European defence

    Banking
    News article image depicting a significant business meeting with diverse executives discussing strategy around a conferenc...

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy